CG Oncology Common stockNASDAQ: CGON

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Website:

http://cgoncology.com

Next earnings report:

30 August 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$2.12 B
-33%vs. 3y high
83%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

3.73
-27%vs. 3y high
77%vs. sector

PS ratio

4.01 K
-75%vs. 3y high
99%vs. sector

Price

after hours | Fri, 05 Jul 2024 20:20:00 GMT
$31.88+$0.29(+0.92%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.36-$0.37

Revenue

Revenue target

$529.00 K$180.00 K

Revenue

Net income

$529.00 K-$16.93 M

Analysts recommendations

Total assets

Total liabilities

$579.11 M$10.17 M

Institutional Ownership

Included in screeners

Mid cap companies
Top performing stocks today
Stocks with price below SMA 200
Stock with high historical volatility
Stocks with high beta
Price lower than analysts target
Analysts recommendations: buy
Stocks with high Altman Z score

Similar companies

CONMED logo

CONMED (CNMD)

QuidelOrtho logo

QuidelOrtho (QDEL)

RxSight logo

RxSight (RXST)

Intellia Therapeutics logo

Intellia Therapeutics (NTLA)

Amneal Pharmaceuticals logo

Amneal Pharmaceuticals (AMRX)

Patterson Companies logo

Patterson Companies (PDCO)

Indivior (INDV)

Protagonist Therapeutics logo

Protagonist Therapeutics (PTGX)

CGON Latest News

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
globenewswire.com24 May 2024 Sentiment: POSITIVE

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS).

What type of business is CG Oncology Common stock?

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

What sector is CG Oncology Common stock in?

CG Oncology Common stock is in the Healthcare sector

What industry is CG Oncology Common stock in?

CG Oncology Common stock is in the Biotechnology industry

What country is CG Oncology Common stock from?

CG Oncology Common stock is headquartered in United States

What is CG Oncology Common stock website?

https://cgoncology.com

Is CG Oncology Common stock in the S&P 500?

No, CG Oncology Common stock is not included in the S&P 500 index

Is CG Oncology Common stock in the NASDAQ 100?

No, CG Oncology Common stock is not included in the NASDAQ 100 index

Is CG Oncology Common stock in the Dow Jones?

No, CG Oncology Common stock is not included in the Dow Jones index

When does CG Oncology Common stock report earnings?

The next expected earnings date for CG Oncology Common stock is 30 August 2024